Top

11-02-2017 | Heart failure | Review | Article

Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus

Journal: Current Heart Failure Reports

Authors: Amanda Trang, David Aguilar

Abstract

Purpose of Review

Diabetes and heart failure commonly coexist and portend worsened prognosis than either disease alone. We explore mechanisms that may serve as potential treatment targets and review the effects of various contemporary glucose-lowering agents on heart failure outcomes.

Recent Findings

Promising data has emerged on sodium-glucose cotransporter 2 (SLGT2) inhibitors as the first class of agents to improve cardiovascular mortality and heart failure outcomes in diabetic individuals both with and without established heart failure.

Summary

Poor glycemic control is linked to worse heart failure outcomes; however, targeting glycemic control alone has not been sufficient. Furthermore, multiple commonly used antihyperglycemic agents may lead to adverse heart failure effects. SGLT2 inhibitors target multiple mechanisms implicated in diabetes and heart failure and may play a promising role in primary prevention of heart failure and in treatment of individuals with diabetes and established heart failure.

Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet (London, England). 2016;388(10053):1545–602. https://doi.org/10.1016/S0140-6736(16)31678-6.CrossRef

Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–18. https://doi.org/10.1056/NEJMoa1608664. CrossRefPubMed

Emerging Risk Factors C, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41. https://doi.org/10.1056/NEJMoa1008862.CrossRef

Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.CrossRefPubMed

Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–13. https://doi.org/10.1016/S2213-8587(14)70219-0.CrossRefPubMedPubMedCentral

Martinez-Selles M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouilloy C, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail. 2012;14(5):473–9. https://doi.org/10.1093/eurjhf/hfs026.CrossRefPubMed

Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J. 2007;154(2):277.e1–8. https://doi.org/10.1016/j.ahj.2007.05.001.CrossRef

MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377–85. https://doi.org/10.1093/eurheartj/ehn153.CrossRefPubMed

Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan in acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004;110(12):1572–8. https://doi.org/10.1161/01.cir.0000142047.28024.f2.CrossRefPubMed

10.

Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213–23. https://doi.org/10.1161/circulationaha.106.679597.CrossRefPubMed

11.

• Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–502. https://doi.org/10.1161/CIRCULATIONAHA.116.022194. This article reviews the disease mechanisms and currently recommended clinical management of cardiovascular disease and heart failure in diabetic patients. CrossRefPubMedPubMedCentral

12.

Abel ED, O'Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012;32(9):2068–76. https://doi.org/10.1161/ATVBAHA.111.241984.CrossRefPubMedPubMedCentral

13.

Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999;22(7):1186–90.CrossRefPubMed

14.

Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation. 2002;105(15):1861–70.CrossRefPubMed

15.

Kosmala W, Sanders P, Marwick TH. Subclinical myocardial impairment in metabolic diseases. JACC Cardiovasc Imaging. 2017;10(6):692–703. https://doi.org/10.1016/j.jcmg.2017.04.001.CrossRefPubMed

16.

Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103(22):2668–73.CrossRefPubMed

17.

Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140–6. https://doi.org/10.1016/s0140-6736(11)60471-6.CrossRefPubMed

18.

Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007;115(11):1371–5. https://doi.org/10.1161/circulationaha.106.661405.CrossRefPubMed

19.

Barzilay JI, Kronmal RA, Gottdiener JS, Smith NL, Burke GL, Tracy R, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43(12):2236–41. https://doi.org/10.1016/j.jacc.2003.10.074. CrossRefPubMed

20.

Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, et al. HbA 1c as a risk factor for heart failure in persons with diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetologia. 2008;51(12):2197–204. https://doi.org/10.1007/s00125-008-1164-z. CrossRefPubMed

21.

Erqou S, Lee CT, Adler A. Intensive glycemic control and the risk of heart failure in patients with type 2 diabetes. Am Heart J. 2012;163(5):e35; author reply e7. https://doi.org/10.1016/j.ahj.2012.02.021.CrossRefPubMed

22.

Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. 2010;59(8):2020–6. https://doi.org/10.2337/db10-0165.CrossRefPubMedPubMedCentral

23.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. https://doi.org/10.1056/NEJMoa0802743.CrossRef

24.

ADVANCE Collaboration Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72. https://doi.org/10.1056/NEJMoa0802987. CrossRef

25.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. https://doi.org/10.1056/NEJMoa0808431. CrossRefPubMed

26.

Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–98. https://doi.org/10.1007/s00125-009-1470-0.CrossRefPubMed

27.

Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, et al. Contributory risk and Management of Comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e535–e78. https://doi.org/10.1161/CIR.0000000000000450. CrossRefPubMed

28.

Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009;54(5):422–8. https://doi.org/10.1016/j.jacc.2009.04.049.CrossRefPubMedPubMedCentral

29.

Elder DH, Singh JS, Levin D, Donnelly LA, Choy AM, George J, et al. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail. 2016;18(1):94–102. https://doi.org/10.1002/ejhf.455.CrossRefPubMed

30.

Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J. 2006;151(1):91. https://doi.org/10.1016/j.ahj.2005.10.008. CrossRefPubMed

31.

Tomova GS, Nimbal V, Horwich TB. Relation between hemoglobin a(1c) and outcomes in heart failure patients with and without diabetes mellitus. Am J Cardiol. 2012;109(12):1767–73. https://doi.org/10.1016/j.amjcard.2012.02.022.CrossRefPubMedPubMedCentral

32.

American Diabetes Association. 6. Glycemic targets. Diabetes Care. 2017;40(Suppl 1):S48–56. https://doi.org/10.2337/dc17-S009.CrossRef

33.

American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Suppl 1):S64–74. https://doi.org/10.2337/dc17-S011.CrossRef

34.

Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338(4):265–6. https://doi.org/10.1056/NEJM199801223380415.CrossRefPubMed

35.

Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4(1):53–8. https://doi.org/10.1161/CIRCHEARTFAILURE.110.952556.CrossRefPubMed

36.

Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53(12):2546–53. https://doi.org/10.1007/s00125-010-1906-6.CrossRefPubMed

37.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–51.CrossRefPubMed

38.

MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. general practice research database. Diabetes Care. 2010;33(6):1213–8. https://doi.org/10.2337/dc09-2227.CrossRefPubMedPubMedCentral

39.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111(5):583–90. https://doi.org/10.1161/01.CIR.0000154542.13412.B1.CrossRefPubMed

40.

Roumie CL, Min JY, Agostino-Mcgowan L, Presley C, Grijalva CG, Hackstadt AJ et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc. 2017;6(4):e005379. https://doi.org/10.1161/JAHA.116.005379.

41.

Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L et al. Comparative safety and effectiveness of metformin in patients with diabetes and heart failure: systematic review of observational studies involving 34000 patients. Circ Heart Fail. 2013;6(3):395-402. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000162.

42.

Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care. 2007;30(12):e129. https://doi.org/10.2337/dc07-1686.CrossRefPubMed

43.

Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731. https://doi.org/10.1136/bmj.b4731.CrossRefPubMedPubMedCentral

44.

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773–8. https://doi.org/10.2337/dc07-0717.CrossRefPubMed

45.

Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH, American Heart Association, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American college of cardiology foundation. J Am Coll Cardiol. 2010;55(17):1885–94. https://doi.org/10.1016/j.jacc.2010.02.014. CrossRefPubMed

46.

Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824–31. https://doi.org/10.1093/eurheartj/ehp604.CrossRefPubMedPubMedCentral

47.

Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–36. https://doi.org/10.1016/s0140-6736(07)61514-1.CrossRefPubMed

48.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35. https://doi.org/10.1016/s0140-6736(09)60953-3.CrossRefPubMed

49.

Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11(8):861–6. https://doi.org/10.1038/nm1278.CrossRefPubMed

50.

Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II heart failure. J Am Coll Cardiol. 2007;49(16):1696–704. https://doi.org/10.1016/j.jacc.2006.10.077.CrossRefPubMed

51.

Waldrop G, Zhong J, Peters M, Rajagopalan S. Incretin-based therapy for diabetes: what a cardiologist needs to know. J Am Coll Cardiol. 2016;67(12):1488–96. https://doi.org/10.1016/j.jacc.2015.12.058. CrossRefPubMedPubMedCentral

52.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://doi.org/10.1056/NEJMoa1501352.CrossRefPubMed

53.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. https://doi.org/10.1056/NEJMoa1307684. CrossRefPubMed

54.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. https://doi.org/10.1056/NEJMoa1305889. CrossRefPubMed

55.

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. https://doi.org/10.1161/CIRCULATIONAHA.114.010389. CrossRefPubMed

56.

Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76. https://doi.org/10.1016/s0140-6736(14)62225-x.CrossRefPubMed

57.

Verma S, Goldenberg RM, Bhatt DL, Farkouh ME, Quan A, Teoh H, et al. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open. 2017;5(1):E152–e77. https://doi.org/10.9778/cmajo.20160058.CrossRefPubMedPubMedCentral

58.

Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al. A multicenter observational study of Incretin-based drugs and heart failure. N Engl J Med. 2016;374(12):1145–54. https://doi.org/10.1056/NEJMoa1506115. CrossRefPubMed

59.

•• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827. A randomized controlled trial in diabetic individuals with high cardiovascular risk that demonstrated liraglutide was associated with decreased advese cardiovascular events compared to placebo. CrossRefPubMedPubMedCentral

60.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. https://doi.org/10.1056/NEJMoa1509225.CrossRefPubMed

61.

Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–8. https://doi.org/10.1001/jama.2016.10260.CrossRefPubMedPubMedCentral

62.

• Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72. https://doi.org/10.1161/CIRCULATIONAHA.116.021887. This article discusses potential pathophysiologic mechanisms through which SGLT-2 inhibitors work to affect cardiovascular and renal benefits. CrossRefPubMed

63.

Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140–51. https://doi.org/10.1016/S2213-8587(13)70050-0.CrossRefPubMed

64.

•• Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720. A landmark clinical trial which demonstrated empagliflozin was associated with reduced adverse cardiovascular events and significant reductions in heart failure hospitalization in patients at high risk for cardiovascular events. CrossRefPubMed

65.

• Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526–34. https://doi.org/10.1093/eurheartj/ehv728. This follow-up study of the EMPA-REG OUTCOME trial highlighted the reduced rates of heart failure hospitalization and cardiovascular death with empagliflozin use in patients with diabetes and cardiovascular disease. CrossRefPubMedPubMedCentral

66.

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J. 2017. https://doi.org/10.1093/eurheartj/ehx511

67.

•• Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; https://doi.org/10.1056/NEJMoa1611925. A randomized clinical trial that demonstrated that canagliflozin was associated with reduced adverse cardiovascular events and heart failure hospitaliazation. This randomized trial provided further support for the potential of SGLT2 inhibitors to reduce heart failure.

68.

Kosiborod M, Cavender MA, AZ F, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249–59. https://doi.org/10.1161/CIRCULATIONAHA.117.029190.CrossRefPubMedPubMedCentral

69.

Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1801–2. https://doi.org/10.1056/NEJMc1611290. PubMed

70.

Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–97. https://doi.org/10.1161/CIRCULATIONAHA.113.005081.CrossRefPubMed

71.

Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016;42(4):224–33. https://doi.org/10.1016/j.diabet.2016.05.006.CrossRefPubMed

72.

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62. https://doi.org/10.1111/dom.12127.CrossRefPubMed

73.

Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39(7):1108–14. https://doi.org/10.2337/dc16-0330.CrossRefPubMed

74.

Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. https://doi.org/10.1186/1475-2840-13-28.CrossRefPubMedPubMedCentral

75.

Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512–7. https://doi.org/10.1038/nm.3828.CrossRefPubMed

76.

Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37(42):3192–200. https://doi.org/10.1093/eurheartj/ehw110.CrossRefPubMed

77.

Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017; https://doi.org/10.1001/jamacardio.2017.2275.

78.

Yokoyama H, Gunasegaram S, Harding SE, Avkiran M. Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium. J Am Coll Cardiol. 2000;36(2):534–40.CrossRefPubMed

79.

Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–73. https://doi.org/10.1007/s00125-016-4134-x.CrossRefPubMed

80.

Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker D, Masson G et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. J Am Coll Cardiol Basic Trans Sci. 2017;2(4):347-54; https://doi.org/10.1016/j.jacbts.2017.07.003.

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »